高级检索
    江滨, 廖鹏军. 硼替佐米联合柔红霉素、阿糖胞苷诱导并联合中剂量阿糖胞苷巩固治疗初治老年AML患者的研究[J]. 循证医学, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
    引用本文: 江滨, 廖鹏军. 硼替佐米联合柔红霉素、阿糖胞苷诱导并联合中剂量阿糖胞苷巩固治疗初治老年AML患者的研究[J]. 循证医学, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
    shu
    JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years[J]. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
    Citation: JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years[J]. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
    shu

    硼替佐米联合柔红霉素、阿糖胞苷诱导并联合中剂量阿糖胞苷巩固治疗初治老年AML患者的研究

    Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years

      摘要
    • 摘要: 老年AML因疾病生物学特性和自身因素对治疗的总体反应差,仅40%~50%患者获得CR,早期治疗相关死亡率达10%~25%,长期生存率远低于年轻患者。为改善预后、提高疗效所开展的临床试验,一是对经典化疗药进行剂量探索,如对蒽环类药物和阿糖胞苷,二是将不同作用机制或有一定靶向作用的药物加入到诱导和巩固治疗中,如粒细胞集落刺激因子（G-CSF）、抗CD33单抗、去甲基化药物、组蛋白去乙酰化酶抑制剂以及针对FLT3、c-KIT基因突变的激酶抑制剂等。

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回